Keystone Heart to Accelerate Trials for a New Advanced Cerebral Embolic Protection Device Post author:Sam Post published:August 1, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Janssen R&D Release: Data At ASCO Show Consistent Progression-Free Survival Benefit In Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients Treated With Ibrutinib, Including Those With High-Risk Disease, With Up To Four Years Of Follow-Up June 4, 2017 Argos Surges on Positive Phase III Kidney Cancer Data November 12, 2017 3 Biotech Stocks Able to Weather an Unstable Administration February 9, 2017
Janssen R&D Release: Data At ASCO Show Consistent Progression-Free Survival Benefit In Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients Treated With Ibrutinib, Including Those With High-Risk Disease, With Up To Four Years Of Follow-Up June 4, 2017